FINANCIAL RESULTS 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Inject Kerala Ltd reported weak Q1 FY26 results, with revenue from operations falling to ₹242.12 lakhs from ₹304.54 lakhs in Q1 FY25, a decline of roughly 20.5% year-on-year. Profit after tax also dropped sharply to ₹7.35 lakhs from ₹12.23 lakhs, down about 40% YoY, translating to an EPS of ₹0.05 versus ₹0.08 earlier. Total expenses of ₹232.30 lakhs were primarily driven by stock-in-trade purchases (₹225.86 lakhs), with very thin operating margins. The statutory auditor (S. Mandawat & Co.) issued an unqualified limited review report with no qualifications or emphasis of matter. The company operates a single segment involving cloth trading and pharma commission income.
Negative for shareholders — both top-line and bottom-line contracted meaningfully YoY, signalling continued weakness in the trading business. With a paid-up capital of ₹1,463.48 lakhs against quarterly PAT of just ₹7.35 lakhs, the stock remains very thinly profitable, which may weigh on sentiment.